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 A STUDY TO CORRELATE SERUM PROLACTIN AND 
CHILD PUGH SCORING IN  CIRRHOSIS 
         
 
INTRODUCTION 
Cirrhosis is derived from greek word kirrhos meaning tawny or orange and osis 
meaning condition[1]. It is an end stage complication of continuous 
inflammation of liver parenchyma secondary to multiple etiologies. The 
leading causes of cirrhosis is viral hepatitis and alcohol[1] .Chronic liver 
disease progresses to cirrhosis may occur in weeks as in complete biliary 
obstruction or years in chronic hepatitis. 
 EPIDEMIOLOGY 
The prevalence of cirrhosis is not known exactly, in USA the prevalence is 
about 0.15% ,there are many undiagnosed cirrhosis secondary to NASH and 
Hepatitis C.  Similar level of prevalence is noted in Europe and Asia. Another 
factor which underestimates cirrhosis prevalence is compensated cirrhosis. 
Around  80% of persons on infection with hepatitis C will develop chronic 
infection. Around 20% of those with chronic infection will go on to develop 
cirrhosis. Mostly these persons will be alcoholic and true incidence of hepatitis 
C related cirrhosis cannot be estimated.[2] 
Around 5% will develop chronic infection after encounter with hepatitis B 
virus. Cirrhosis will occur in around 20% of the patients with chronic 
infection.[2] 
Hemochromatosis  leads to cirrhosis in 2% of affected women and 10% of 
affected men. There are no specific data regarding percentage of patients with 
other parenchymal liver disease developing cirrhosis. 
REVERSAL OF FIBROSIS 
Observations from clinical and experimental studies has given hopeful results 
that when the inciting agent is  removed ,there is improvement in hepatic 
histology as shown  after  relieving of obstruction in cholestatic jaundice. The 
pathways targeted for reversing the fibrosis are  angiotensin, tyrosine kinase 
receptor , matrix degrading proteases  and  integrins. These pathways aim at 
reversing the activated hepatic stellate cell by apoptosis, senescence, 
deactivation. Only early stages of fibrosis is reversible, not late stages.[3] 
PROGNOSIS 
On comparing with normal population, patient with decompensated cirrhosis 
will have 10 fold increased risk of death. Patients with compensated cirrhosis 
will have 5 fold increased risk of death . Median survival of patients with 
compensated cirrhosis is  9 to 12 years while patients with decompensated 
cirrhosis is 2 years.[4] 
In Danish population study, survival probability  of cirrhosis patients was 
estimated  to be 66%  at 1 year , 38% at 5 years ,22% at 10 years. In Danish 
study median survival of cirrhotic patients without complications was 4 years, 
1 year survival of 83% for compensated cirrhosis ,80% with variceal 
bleeding,71% with ascites , 51%  with ascites and variceal bleeding and 36% 
with hepatic encephalopathy.[4] 
Prognosis depends not only on the cirrhosis severity but also on the comorbid  
illness present. Scores available to determine the severity of cirrhosis are child-
pugh-turcott scoring and meld score  and Von willebrand factor levels. Apart 
from the complications arising from cirrhosis infections and renal failure are 
also important cause of mortality in cirrhosis.[4] 
 REVIEW OF LITERATURE 
Cirrhosis is a complication occurring in the liver following continuous 
exposure to agents causing hepatic inflammation and damage. The hepatocytes 
are  replaced by fibrotic tissue and normal liver architecture replaced by 
nodular hepatocyte regeneration. Due to loss of functioning hepatocytes, 
various derangements occur in the body manifesting as jaundice, ascites, pedal 
edema, portal hypertension, hypoalbuminemia and leading to complications 
such as spontaneous bacterial peritonitis, hematemesis, hepatorenal syndrome, 
hepatopulmonary syndrome, hepatic encephalopathy, hepatocellular carcinoma, 
cirrhotic cardiomyopathy. Not all cirrhosis will have both fibrosis and 
nodularity like nodular regenerative hyperplasia characterized by only 
nodularity and no fibrosis , schistosomiasis characterized by symmer pipestem 
fibrosis and no nodules.[5] 
CLASSIFICATION 
Cirrhosis classification is based on  morphological and etiological types 
 Morphological classification 
 Macronodular : nodular size more than 3mm 
 Micronodular : nodular size less than 3mm 
 Mixed  pattern : both macronodules and micronodules are seen.  
 Etiological classification  
 It  is based on biochemical, histological ,genetic and epidemiological data by 
which        the   likely agent determined. 
Cryptogenic cirrhosis etiology is most to be non alcoholic steatohepatitis.[5] 
ETIOLOGY OF CIRRHOSIS 
Infections( hepatitis B,C,D) 
Alcohol 
Autoimmune hepatitis 
Cholestasis (primary biliary cirrhosis, secondary biliary cirrhosis, primary 
sclerosing cholangitis) 
Metabolic (Wilson, hemochromatosis, alpha1 antitrypsin deficiency) 
Vascular(budd-chiari syndrome, cardiac cirrhosis, sinusoidal obstruction 
syndrome).[5] 
PATHOGENESIS  OF CIRRHOSIS OF LIVER                                                        
 
 
Hepatic stellate cells are the principal cells which on activation leads to fibrotic 
changes in the liver architecture. These cells are located in the space of disse 
,lying albuminal to the sinusoidal endothelial cells. On activation stellate cells 
transform to myofibroblast , characterized by contractility , motility and actin 
expression.The matrix produced by stellate cells ,fibronectin is the earliest 
matrix, which leads to production of other matrix which leads to deposition of 
collagen and fibrosis occurs. 
Among the various pathways of stellate cell activation, most implicated are the 
kinase activation pathways mediated through platelet derived growth factor and 
integrin signalling pathways. Other cells apart from hepatic stellate cells having 
a role in cirrhosis are hepatic epithelial cell and portal fibroblast. Hepatic 
fibroblast when injured as in case of cholestatic injury in primary biliary 
cirrhosis and primary sclerosing cholangitis leads to cirrhosis .Epithelial cell 
injury  following apoptosis ,cell necrosis will attract stellate cells . Recently 
sinusoidal epithelial cells are also implicated in development of fibrosis. 
Angiogenesis also implicated as it leads to activation of  stellate cells by 
paracrine pathways .[6]  
AST/PLATELET RATIO INDEX: 
BONACINI CIRHOSIS DETERMINANT SCORE: 
LOK INDEX: 
  
ANATOMY OF THE LIVER
 
 Liver is surrounded  by parietal peritoneum except in the bare area of liver , 
which is in direct contact with diaphragm. The peritoneal reflections around the 
bare area of liver are superior coronary ligament , inferior coronary ligament 
,right triangular ligament  and left triangular ligaments. Liver as traditionally 
taught has four lobes named as right lobe ,left lobe, caudate and quadrate lobe 
of liver. The falciform ligament divides liver into right and left lobe , the 
quadrate lobe is defined by gallbladder fossa ,porta hepatis and ligamentum 
teres ,caudate lobe is delineated by inferior venacava groove, porta hepatis and 
ligamentum venousum  fissure. These division is anatomical  and not 
functional division. The true right and left lobe of liver is separated by cantlie’s  
line, an imaginary line drawn from bed of gall bladder fossa and notch of 
inferior vena cava. Functional division of liver is determined by the arterial 
blood supply, portal venous blood supply, biliary drainage and hepatic venous 
drainage, as two segments and these segments are further divided into 
subsegments . Many functional systems  are defined but mostly used system is 
Couinaud (based on portal and hepatic veins) and other system is Healey and 
Scroy(based on bile duct distribution). The subsegments  are assigned from  
one to eight with the caudate lobe assigned number 1 and other subsegments in 
clockwise rotation. [8] 
 
 
VASCULAR SUPPLY 
The liver approximately receives blood supply from both hepatic artery and 
portal vein. Hepatic artery supplies around 60% of oxygen and 30% of blood 
supply. Portal vein supplies 70% of blood and 40% of oxygen. Hepatic artery 
arises from celiac trunk, sometimes it may arise from superior mesenteric 
artery. Common variations are left hepatic artery arising from left gastric artery 
and right hepatic arising from superior mesenteric artery. Portal vein is formed 
by the confluence of superior mesenteric vein and splenic vein. Venous 
drainage is by three hepatic veins draining into inferior vena cava . [9] 
GLISSON’S CAPSULE 
It is an intra parenchymal  fibrous sheath covering the arteries, portal veins and 
bile ducts except hepatic veins. 
NERVE SUPPLY 
Hepatic nerve plexus which runs along portal vein and hepatic artery. 
Sympathetic fibres arise from the celiac plexus , whereas parasympathetic 
arises from the anterior and posterior vagal trunks. Although the function of 
nerve supply is still not clear ,activation  results in vasoconstriction of blood 
vessels. 
Referred pain is perceived in the T9 – L2 segment, around hypochondrium and 
umbilicus. 
   
LIVER CELL TYPES 
HEPATOCYTES 
These cells are polyhedral approximately 20-30micrometre in size. Around 
30% of cells are binucleate and polarized cells. The plasma membrane has 
three surfaces sinusoidal surface, canalicular surface, contiguous surface. The 
sinusoidal and canalicular surface has microvilli. Space of disse is the space 
between sinusoidal villi and  endothelial villi. 
BILE DUCT EPITHELIAL CELLS 
It comprises of large and small subpopulations of cells, whose size correlates 
roughly to the diameter of intra hepatic bile ducts. Endoplasmic reticulum is 
well developed in large cholangiocytes than small cholangiocytes. These cells 
are highly polarized. 
 HEPATIC  SINUSOIDAL ENDOTHELIAL  CELLS 
These cells contribute around 20 % of  liver cells. These cells have 
fenestrations and extensions that form sieve like plates. These cells do not form 
intracellular junctions and simply overlap each other. There is no basement 
membrane and fenestra are present  through which the plasma communicates 
with sinusoidal cells.[10] 
KUPFFER CELLS 
These are specialized tissue macrophages which constitute around 80% - 90% 
of tissue macrophages overall in the body. Remove toxic pathogenic material 
from blood reaching liver through portal vein. The cells are located in 
sinusoidal lumen and are in direct contact with endothelial surface. Numbers 
increase following injury by infectious , inflammatory and chemical agents.[11]   
STELLATE CELLS 
Otherwise known as Ito cells or perisinusoidal cells, located in the peri 
sinusoidal space of disse. Special stain used is gold chloride, routine 
histological  appearance is cell with multiple fat lobules. Stellate cells 
constitute around 5%-8% of total liver cells. It is quiescent  normally. Stellate 
cells store vitamin –A as retinol esters. 
PITCELLS 
These cells are the natural killer cells of the liver. Located in sinusoidal lumen 
along with kupffer cells, adhered to the wall of sinusoids. Cytoplasm contains 
dense granules which appear as pits , hence the name. The pit cells are short 
lived and are replenished from extrahepatic sources. Similar to systemic natural 
killer cells, pit cells represent  OX-18 antigen . They donot  represent pan-T 
cell marker and OX-19. The source of pit cells is still not clear. They might 
have a role to play in graft rejection. 
LIVER FUNCTIONS 
The liver has many functional capabilities in the form of synthetic , catabolic, 
metabolic and detoxification . Synthetic functions include synthesis of plasma 
proteins, clotting factors, glycogen synthesis , bile acid synthesis, carbohydrate 
,protein, lipid metabolism. These functions will be altered in cirrhosis and these 
changes result in complications occurring in cirrhosis. 
Around 100 grams of glycogen is synthesised and stored in hepatocytes via 
glycogenesis. When needed by body these glycogen is broken down into 
glucose  and supplemented to the body. 
Liver also has main function in the protein metabolism both synthesis and 
catabolism. Aminoacids are also synthesised  by the liver . Clotting  factors are 
also synthesised by the liver like fibrinogen, prothrombin, labile factor, 
antihemophillic factor A , christmas factor ,stuart prower factor , Hageman 
factor, fibrin stabilizing factor also with protein c, protein s, antithrombin. The 
first factor to decrease is  antihemophilic factor because of its short half life 
followed by Christmas factor and stuart prower factor . Labile factor is  not  
vitamin k dependent factor ,so prolonged prothrombin time secondary to 
vitamin k deficiency can be ruled out from liver dysfunction. Labile factor can 
also be used as a prognostic marker in patients with acute liver cell failure. 
Values below 20% of normal is a poor prognostic sign.[11] 
In lipid metabolism cholesterol  synthesis occurs along with triglycerides. Liver 
secretes bile which is needs for the emulsification of fat and absorption of 
vitamin K from diet. Part of bile is stored in gall bladder and secreted into 
duodenum. It also produces insulin like growth factor-1, that has an important 
role in childhood growth and has anabolic action in adults.    
 Albumin accounts for  around 65% of total plasma proteins. Each day around 
12-14 grams of albumin is synthesised by liver. Half-life of albumin is 21 days. 
Hypoalbuminemia  occurs secondary to decreased production  or expanded 
plasma volume. It is commonly seen in chronic liver disease and less 
commonly in acute liver cell failure. Hypoalbuminemia is not specific for 
paerenchymal liver disease also occurs in glomerular and gastrointestinal 
losses. Globulins are elevated  nonspecifically in chronic liver disease. The 
pattern of elevation may provide clue to the primary liver disease[12]. 
Elevated IgG – Autoimmune hepatitis 
Elevated IgM – Primary biliary cirrhosis 
Elevated IgA- Alcoholic liver disease. 
ASSESSMEMT OF LIVER FUNCTION 
Liver function test includes test for hepatic synthetic, excretory , 
necroinflammatory activity or cholestasis.  Abnormal liver biochemistry tests 
may be the first clue  to liver disease. Normal or minimally abnormal liver 
biochemical tests doesnot preclude significant liver disease . 
SERUM BILIRUBIN 
Serum bilirubin is mostly the first evidence of underlying liver disease. 
Clinically detectable when serum bilirubin level more than 3mg/dl. Associated 
passage of dark urine or pale stool  before eye manifestation occurs. Bilirubin 
is a metabolised product of heme  rich proteins or enzymes . Following  its 
release into blood it is bound with albumin , taken up by hepatocytes and 
metabolically converted from water insoluble form to water soluble form  by 
glucuronide conjugation. The conjugated bilirubin is secreted via canalicular 
membrane into bile. When serum levels of conjugated bilirubin rises, it binds 
with albumin to form delta bilirubin ,so it is not excreted so bilirubin level 
decreases after few days of recovery until these delta bilirubin are metabolized 
by liver. Few amount of excreted conjugated bilirubin is reabsorbed after  
deconjugation and intestinal bacterial action reduced to urobilinogens and 
reabsorbed by the enterohepatic circulation Hyperbilirubinemia is classified 
into unconjugated , conjugated and very high bilirubin levels. 
Unconjugated  bilirubinemia (less than 7 mg/dl) occurs secondary to hemolysis, 
ineffective erythropoiesis, gilberts syndrome. 
Conjugated  bilirubinemia occurs in dubin jhonson syndrome, rotor syndrome, 
bile transport protein defects, intrahepatic or extrahepatic cholestasis. 
Very high bilirubin levels more than 30mg/dl signifies hemolysis alomg with 
parenchymal liver pathology or biliary obstruction . More than 60mg/dl occurs 
in hemoglobinopathies and along with acute hepatitis and obstructive jaundice. 
Urine bilirubin positivity indicates   increased conjugated hyperbilirubinemia. 
Urinary urobilinogen is found in patients with hemolysis, gastrointestinal  
hemorrhage or hepatocellular disease. Absence of urobilinogen in urine is 
suggestive of obstructive pathology of bile ducts. 
Serum  bilirubin is measured by  van den bergh  reaction, indirect bilirubin is 
estimated from subtracting direct bilirubin from total bilirubin. 
SERUM AMINOTRANSFERASES 
These are intracellular enzymes released from  damaged hepatocytes . 
Aspartate aminotransferase found in both cytosol and mitochondria .Other 
tissues from which it will be released following injury is heart ,kidney ,brain , 
pancreas, skeletal muscle. Also called as serum glutamic oxaloacetic 
transaminase. Normal AST levels 10 to 40 units/l. 
Alanine aminotransferase is found only in cytosol ,highest concentration in 
liver, more specific for liver injury than aspartate amino transferase. In men 
level upto 30u/l is normal , in females level upto 19u/l is normal. Also called as 
serum glutamic pyruvic transaminase. 
In alcoholic hepatitis aspartate amino transferase levels  are less than 10 times 
the normal and a ratio of 2:1 is maintained between  aspartate aminotransferase 
and alanine aminotransferase. The lower elevation of alanine aminotransferase 
is secondary to decreased pyridoxal phosphate   in alcoholics[13]. 
In viral ,toxic and ischemic hepatitis enzyme levels will be in a ratio of 1:1 and  
will be more than 1000u/l. Mild to moderate elevations are seen in chronic viral 
hepatitis , autoimmune hepatitis ,hemochromatosis ,Wilson disease, alpha1 
antitrysin deficiency.[13] 
 
SERUM ALKALINE PHOSPHATASE  
This enzyme not in hepatocyte , present in biliary canalicular membrane . 
Alkaline phosphatase  has multiple isoenzyme forms. This test is sensitive for 
detection of biliary tract obstruction. Half life of alkaline phosphatase is 17 
days. Levels remain elevated upto 1 week release of obstruction. The elevation 
is secondary to increased synthesis from liver  apart from leakage from bile 
duct cells and removal from circulation by hepatocytes. Isolated elevation of 
alkaline phosphatase  occurs in infiltrative liver diseases such as tumour, 
abscess , granulomas,and amyloidosis. High levels are seen in sclerosing 
cholangitis, primary biliary cirrhosis, sepsis, acquired immunodeficiency 
diseases and drug related cholestatic liver injury. Other than liver other causes 
of elevated  alkaline phosphatase are bone , intestine ,kidney , placenta. Other 
causes are pagets disease of bone , intestinal obstruction, osteoblastic bone 
secondaries. The hepatic and non hepatic cause of elevated alkaline 
phosphatase  can be differentiated by estimating either serum gamma glutamyl 
transpeptidase or 5 nucleotidase. Low levels of alkaline phosphatase is seen in 
hypothyroidism, pernicious anemia , fulminant Wilsons disease, zinc 
deficiency, congenital hypophosphatasia[14]. 
GAMMA GLUTAMYL TRANSPEPTIDASE 
It is found in many different organs , high concentrations are seen in cells 
lining biliary canaliculi. It is a sensitive indicator but not specific for 
hepatobiliary disease.  Elevations are seen in diabetes mellitus, myocardial 
disease, pancreatic disease, renal failure. It is an inducible enzyme elevated 
following intake of phenytoin or alcohol. Half life is around 26 days. Its role as 
marker of alcohol abuse detection is limited.  Major use to rule out bony  
causes of elevation of elevated alkaline phosphatase[15]. 
5’ NUCLEOTIDASE 
 It is found in liver canaliculi and sinusoidal plasma membrane. Elevated 5 
nucleotidase along with alkaline phosphatase  is specific for hepatobiliary 
dysfunction[16]. 
LACTATE DEHYDROGENASE 
Lactate dehydrogenase  has 5 isoenzymes  of which liver specific is  LDH5 
isoenzyme.  Elevated in conditions like shock, hepatocellular necrosis, cancer 
and hemolysis. 
TEST FOR  HEPATIC METABOLIC FUNCTIONS 
ANTIPYRINE CLEARANCE 
 Metabolism done by   cytochrome P-450 enzyme system . In chronic liver 
disease the metabolism time prolonged ,so halflife is increased.  Good relation 
exists between antipyrine half life and disease severity. Disadvantage is 
multiple blood sampling is required[17]. 
AMINOPYRINE TEST  
It is based on detecting 14 carbon labelled carbon dioxide in breath after 
administration of dimethyl amino antipyrine. Impairment occurs in both acute 
and chronic liver disease.  In patients diagnosed to have chronic liver pathology 
and alcoholic hepatitis, prognosis can be assessed by doing this test[18]. 
CAFFEINE CLEARANCE TEST 
 Estimated  in saliva or serum  after oral intake. The accuracy is similar to the 
aminopyrine breath test . Not useful in estimating minor liver dysfunctions. 
Abnormal results possible  in persons with smoking and  proton pump 
inhibitors like cimetidine[18].  
GALACTOSE ELIMINATION CAPACITY 
 It is  cleared  from blood by phosporylation of galactose  in liver  30- 40 
minutes  after  oral or intravenous administration. Hepatic functional mass is  
indicated  when serum has more than 50mg/dl. When blood level is less than 
50mg/dl it denotes about the blood flow to liver. Clearance is impaired in acute 
and chronic liver disease . Also in patients with metastatic hepatic neoplasms .    
In obstructive jaundice clearance is not impaired[18]. 
LIDOCAINE METABOLITE 
 Monoethlyglcinexylidide is a product of hepatic metabolism of lidocaine . 
Assessed by fluorescence polarization immune assay . It  provides prognostic 
information about chance of life threatening effects .  Assessment of  the 
viability of donor liver allografts is done by this test[18]. 
OTHER LIVER FUNCTION TESTS 
SERUM BILE ACIDS  
Bile acids   are products of cholesterol metabolism  in liver along with 
conjugation either with  taurine or glycine  and excreted from liver as bile .  
Bile acids  are  helpful in fat micelles emulsification and absorption through 
lymphatics in the small intestine. Enterohepatic circulation  is a mechanism by 
which part of bile acids secreted is reabsorbed. Secondary bile acids form by 
the action of intestinal bacteria by deconjugation.  Serum bile acids raise  is a 
marker of hepatobiliary  pathology .  No advantage  over measuring a single 
bile acid or total bile acids . Normal serum bile acids with elevated 
unconjugated  hyperbilirubinemia likely indicate  hemolysis and  or gilbert 
syndrome. 
 SYNTHESIS OF UREA  
Urea is obtained from metabolism of proteins .  The excretion from body occur 
from urine and  intestine where urea is lysed to ammonia  and carbon dioxide.  
Urea production  can be assessed from estimation of urine urea excretion and 
blood urea nitrogen .It is not useful for assessment of  liver dysfunction in 
compensated cirrhosis[18]. 
BROMOSULPHALEIN 
Bromosulphalein clearance after intravenous dosing was used to assess liver 
synthetic function .  But this test  fell out of favour because of reports of severe 
allergic reactions, lack of accuracy in distinguishing hepatocellular from 
obstructive jaundice[18]. 
INDOCYANINE GREEN 
It is metabolized by the liver after intravenous administration. Bloodlevel 
estimated after 20 minutes of administration. The hepatic clearance of 
indocyanine green is through liver and it is minimally toxic. Its reliability in 
assessment of  liver dysfunction not better than  child pugh turcotte 
scoring[18]. 
PATHOLOGY OF CIRRHOSIS[19] 
Liver biopsy is performed in selected patients in whom clinical, biochemical , 
radiological data are not suggestive of cirrhosis. 
GROSS EXAMINATION 
Liver surface is irregular, with multiple yellowish nodules , depending on the 
stage of cirrhosis ,liver may be  enlarged secondary to regenerating nodules or 
shrunken as in end stages of cirrhosis. 
PATHOLOGIC CRITERIA FOR CIRRHOSIS 
Regenerating nodules 
Fibrosis  
Regenerative hyperplasia 
Abnormal hepatic architexture 
Hepatocellular abnormalities 
Fragmentation of the samples 
Dysplasia 
Hepatocellular abnormalities 
pleomorhism 
INFORMATION  FROM MICROSCOPY 
Presence of fibrosis 
Cause of cirrhosis 
Grade of cell activity 
SPECIAL METHODS AND STAININGS 
Iron content estimation  for hemochromatosis 
Per iodic acid Schiff and diastase for alpha-1 antitrysin 
Copper content for wilson 
Immunohistochemistry for hepatitis B virus 
Polymerase chain reaction for hepatitis C virus. 
CLINICAL FEATURES 
Cirrhosis has protean manifestations. A patient with cirrhosis may present with 
few or all or none of the following findings 
General  features 
Fatigue , fever, weightloss,  wasting, malaise. 
Gastrointestinal  
Parotid salivary gland enlargement , loose stools, gall stones, bleeding from the 
bowel( esophageal,  rectal and  stomal varices, portal hypertensive gastropathy) 
Changes in hematology 
Anemia (folic acid deficiency,  zieve syndrome, hyperspleenism induced 
pancytopenia), decreased platelet and white blood cell count, impaired clotting, 
consumption coagulopathy, iron overload toxicity. 
Respiratory features 
Decreased  blood oxygen levels, portopulmonary hypertension, altered 
ventilation perfusion, hyperventilation, reduced pulmonary diffusion , hepatic 
hydrothorax( usually right sided, in patients with cirrhosis without primary 
pulmonary and cardiac disease) 
 Hepatopulmonary syndrome(triad of  an increased alveolar arterial gradient 
while breathing room air , intravascular dilatations  and  liver disease) 
characterized by   orthodeoxia, clubbing and hypoxemia. Intrapulmonary 
shunting  evidenced  with constrast enhanced bubble echocardiography. In 
absence of  liver transplantation mortality is high. Condition reverses  after 
liver transplant. 
Cardiac complication is secondary to hyperdynamic circulation because of 
vasodilatation. 
Renal complications is due to aldosterone release in view of decreased 
intravascular volume ,  hepatorenal syndrome. 
Endocrine changes 
Hypogonadism (loss of libido, testicular atrophy,  decreased amounts of  
testosterone for male patients) 
Infertility , loss of secondary sexual characteristics, dysmenorrhoea for female 
patients. 
Feminization ( palmar erythema, breast enlargement, hair loss, loss of axillary  
and trunk hair, spider naevus) and diabetes mellitus. 
Nervous system complications 
Hepatic encephalopathy and its types such as spastic paraplegia and acquired  
hepato -cerebral degeneration.  Peripheral nerve involvement , non dominant 
parietal lobe involvement in the form of asterixis. 
Skeletal and Muscular system 
 Muscle mass loss secondary to protein catabolism, clubbing ,periosteal pain, 
synovial reaction, osteodystrophy secondary to liver diseases, muscle spasms, 
paraumbilical hernia due to muscle weakness. 
Skin related changes 
Spider naevus, nail changes(azure lunules, terry nails, muerckes nails ),scratch 
marks secondary to itching in cholestatic disease , palmar erythema,  dupytrens 
contracture, clubbing, jaundice, caput medusa, easy bruising. 
DIAGNOSIS OF CIRRHOSIS 
Physical examination  
Characteristic features of chronic  parenchymal liver disease  like palmar 
erythema, spider naevus, dupyterns contracture ,  breast enlargement, testicular 
atrophy. 
Portal hypertension features like  spleenomegaly, fluid collection in 
peritoneum, dilated veins around umbilicus,  hyperdynamic circulation 
indicated by tachycardia, cruveilhier baumgarten syndrome( collateral through 
patent umbilical vein) 
Hepatic encephalopathy features like , flapping tremors,  altered sleep pattern , 
fetor hepaticus. And other features like jaundice,  parotid enlargement, scanty 
trunk and axillary hair. 
 
 
 
 
 
CHILD PUGH SCORING[19]. 
CLINICAL AND LAB 
CRITERIA 
 
1 
 
POINTS 
2 
 
             3 
 
ENCEPHALOPATHY 
 
ASCITES 
 
 
BILIRUBIN 
 
ALBUMIN (g/dl) 
 
PROTHROMBIN 
TIME (SECONDS 
OVER CONTROL) 
 
INR 
 
 
NONE 
 
NONE 
 
 
<2 
 
>3.5 
 
<4 
 
 
 
<1.7 
 
GRADE I or II 
 
MILD TO MODERATE 
(DIURETIC RESPONSIVE) 
 
2-3 
 
2.5-3.5 
 
4-6 
 
 
 
1.7 
 
GRADE III or IV 
 
SEVERE 
(DIURETIC RESISTANT) 
 
>3 
 
<2.5 
 
>6 
 
 
 
1.7-2.3 
CLASS A 
 
CLASS B 
 
CLASS C 
5-6 
 
7-9 
 
10-15 
  
 LABORATORY EVALUATION 
Hepatocellular injury  pattern causes  elevations of aspartate aminotransferase 
and alanine aminotransferase. 2:1 ratio of AST/ ALT in alcoholic patients. In 
chronic hepatitis of most etiology except alcohol will have AST/ALT ratio equl 
to 1 .  As the chronic hepatitis  progresses  ,the ratio  becomes same or reversed  
AST/ALT.   
Tests for cholestasis 
Alkaline phosphatase, conjugated and unconjugated bilirubin , gamma 
glutamyl transpeptidase and 5 nucleotidase. 
Tests for synthetic function 
Assessed by prolongation of prothrombin time [20]and serum albumin level. 
TEST TO DETERMINE THE ETIOLOGY 
Viral markers for both hepatitis B and C virus, polymerase chain reaction   to 
determine   RNA or DNA , serum iron,  total iron binding capacity , ferritin, 
genetic mutation for HFE gene mutation,  urine copper levels and serum 
ceruloplasmin levels , alpha -1 antitrypsin level and protease inhibitor,  for 
diagnosing autoimmune hepatitis  serum immunoglobulins level are estimated , 
autoantibodies : antinuclear antibody, antimitochondrial antibody, anti liver 
kidney microsomal antibody,anti smooth muscle antibody for primary biliary 
cirrhosis amd autoimmune hepatitis respectively. Alpha feto protein level to 
screen for hepatocellular carcinoma. 
IMAGING STUDIES 
Abdominal ultrasonography which is non invasive ,relatively inexpensive ,can 
easily detects ascites , biliary dilatation, screening for hepatocellular 
carcinoma, duplex doppler   ultrasonography for hepatic and portal vein  
patency[21]. 
Computed tomography, expensive than ultrasonography, findings in cirrhosis 
are non –specific, may be helpful in the diagnosis of hemochromatosis, 
increased density of liver is suggestive[21]. 
Magnetic resonance imaging 
Non invasive, expensive than computed tomography, better mode to 
differentiate suspicious liver lesions, can assess the hepatic vasculature status  
without constrast and Doppler ultrasound, may detect iron overload (black 
hypointense liver), magnetic resonance cholangiography for biliary tree 
imaging[21]. 
Radionuclide studies 
Technetium-99 sulfur colloid may help in detecting cirrhosis(increased uptake 
in bone marrow and spleen and not by liver)[22]. 
Esophago gastroduodenoscopy  to determine esophageal varices 
LIVER BIOPSY 
Gold standard for diagnosis of cirrhosis, done by either percutaneous  or 
transjugular or laparotomy or laparascopy. Complication possible are bleeding , 
infection, pneumothorax, pain ,hypotension[23]. 
TREATMENT  
Treatment options present for a few causes of cirrhosis like phlebotomy for 
hemochromatosis, d-peniciilamine for Wilsons disease ,avoidance of alcohol 
for alcohol induced cirrhosis, peg interferon alpha for chronic hepatitis C, for 
hepatitis B lamivudine , adefovir, entecavir, telbivudine, tenofovir , steroids for 
autoimmune hepatitis, ursodeoxycholic acid for primary biliary cirrhosis. 
Treatment also aims towards preventing of complications and for occurred 
complications 
Every  6 month screening with ultrasound and serum alpha fetoprotein levels 
for hepatocellular carcinoma. 
Vaccination is advised for patients with cirrhosis for hepatitis A and hepatitis 
B. 
Cirrhotic patients should avoid alcohol and hepatotoxins. 
 In end stage cirrhosis , liver transplantation is treatment of choice if the patient 
is appropriate candidate. 
 
COMPLICATIONS OF CIRRHOSIS 
Portal hypertension ,ascites, spontaneous bacterial peritonitis, variceal 
hemorrhage, hepatic encephalopathy, hepatocellular carcinoma, hepatorenal 
syndrome. 
Portal hypertension 
It is defined as increase in portal venous pressure gradient leading to opening 
up of collaterals which  form communication between portal and systemic 
veins which help the portal blood to bypass the liver. The ultimate change 
occurring is the increased intrahepatic endothelin and decreased intrahepatic 
nitric oxide . The normal portal pressure is 5 to 10mmhg. Portal hypertension is 
said to present when portal pressure is more than 12mmhg. The normal portal 
blood flow is 1 to 1.5 ltr/minute. Portal hypertension is caused by multiple 
etiologies among which cirrhosis of liver is also one among the important 
cause[24]. Portal hypertension is classified as prehepatic, intrahepatic and 
posthepatic. 
Intrahepatic causes is further classified into presinusoidal , sinusoidal ,post 
sinusoidal.there is overlap present in this classification system. 
CAUSES OF PORTAL HYPERTENSION 
Clinical effects of portal hypertension 
Varices :gastroesophageal, anorectal, retroperitoneal and stomal. 
Portal hypertensive gastropathy, enteropathy and colopathy. 
Caput medusa 
Ascites and hepatic hydrothorax 
Spontaneous bacterial peritonitis. 
Spleenomegaly and hyperspleenism 
Hepatic encephalopathy. 
Portal pressure measurement 
In majority of cases the diagnosis of portal hypertension is based on clinical 
findings, however  in some cases portal pressure measurement is done. Patency 
of the portal vein is assessed first before measuring the pressure. Two types of 
measurement are available direct and indirect. Direct measurement is accurate 
,invasive , and expensive. Indirect measurement is less invasive ,safer and 
preferred method over direct measurement. 
Treatment of portal hypertension  
Pharmacotherapy  
Two classes of drugs are used for the trearment of portal hypertension 
vasoconstrictors and vasodilators. 
Vasoconstrictors used are vasopressin, somastostatin, nonselective beta 
blockers. These drugs reduce splanchnic blood flow that leads to a reduction in 
portal blood flow and pressure. 
Vasodilators used are nitroglycerin, long acting nitrates , prazosin, angoitensin 
inhibitors. These drugs act by altering resistance by inducing changes in the 
intrahepatic perivenular and perisinusoidal myofibroblats and smooth muscles, 
there by reducing the pressure[25]. 
Non selective beta blocker therapy is indicated for patients in child –a and b 
classes, good compliance to medications and no contraindications for beta 
blockers. 
Endoscopy 
Variceal ligation  of the varices has comparable success rate those achieved 
with propanalol. 
Surgical  
Eventhough portosystemic shunt surgery markedly decrease the development 
of variceal hemorrhage  there have been reports of increased incidence of 
hepatic encephalopathy and decreased survival . Shunt procedures is not 
indicated for the prevention of initial variceal hemorrhage. 
Treatment options for failed medical therapy 
Transjugular intrahepatic portosystemic shunt  
For low risk individuals portosystemic shunt surgery is an option. 
Liver transplantation should always be considered in patients with end stage 
liver disease. 
Management of non esophageal varices related to portal hypertension 
Gastric varices that extend 5cm below the gastroesophageal junction has high 
risk of bleeding  , application of cyanoacrylate glue has been more effective 
than variceal banding. Complications include bacteremia and glue 
embolization. 
Portal hypertensive gastropathy is a common complication of portal 
hypertension but significant bleeding is uncommon. Only pharmacologic 
therapy has a role, no role for endoscopic ligation. Severity varies from diffuse 
mosaic mucosal pattern to diffuse mucosal haemorrhages. 
Management of acute variceal bleeding 
Endoscopic  variceal ligation is the treatment of choice in acute variceal 
haemorrhages.  Success rate is around 80% to 90% in initial control of variceal 
bleeding [26]. Pharmacologic drugs used in acute variceal bleeding is 
vasopressin , nitroglycerin ,somatostatin, octreotide analogues .treatment 
should be continued for 5 days. Rarely ballon tamponade is used nowadays but 
still useful in cases with endoscopic and pharmacological treatment failure. 
Ascites  
It  is the pathologic accumulation of fluid in peritoneal cavity. Around 85% of 
cause is secondary to cirrhosis. The theory explaining the accumulation of fluid 
are underfill theory, overfill theory and peripheral arterial vasodilatation. The 
ascites in cirrhosis is usually insidious onset , acute onset ascites is seen in 
buddchiari syndrome ,pancreatic ascites following acute pancreatitis.it can be 
detected clinically by shifting dullness  when peritoneal fluid is more than 
1500ml. Ultrasound can detect  as minimal as 100ml of ascitic fluid[27] . 
Grading of  ascites  
Grade-1  detectable after careful clinical examination 
Grade-2   easily detected but small amount  
Grade -3  obvious but not tense  
Grade-4- tense 
Refractory ascites is the one which cannot be removed or prevented by medical 
therapy. The two types of refractory ascites are diuretic resistant and diuretic 
intractable ascites. Diuretic resistant ascites is lack of response to salt 
restriction and maximum diuretic use. Diuretic intractable ascites is 
complications that preclude the use of diuretics. 
Analysis of ascitic fluid 
New onset ascites , routine admission or readmission of patients with 
ascites,clinical features suggestive of ascitic fluid infection such as fever, 
abdominal pain ,elevated total count, encephalopathy and renal impairment. 
Ascitic fluid is tapped by Z tract technique so prevent continuous oozing of 
ascitic fluid from tapping site .There is no contraindication for ascitic fluid 
tapping ,even in coagulopathy tapping is done. It gives clue regarding the cause 
of ascites. The various parameters estimated in ascitic fluid is cell count 
,protein , sugar, culture, albumin, total protein,amylase, lactate dehydrogenase , 
gram stain, triglyceride, bilirubin, cholesterol, alpha fetoprotein, fibronectin. 
The single most important investigation is cell count to rule out ascitic fluid 
infection. 
Serum ascites albumin gradient 
A saag of 1.1g/dl or more is suggestive of portal hypertension induced ascites , 
a low saag indicates non portal hypertension induced ascites. 
High SAAG ascites: cirrhosis, alcoholic hepatitis, cardiac ascites, massive liver 
metastases, fulminant  hepatic failure,  budd chiari syndrome, portal vein 
thrombosis,sinusoidal obstruction syndrome,acute fatty liver of pregnancy, 
myxedema, mixed ascites. 
Low SAAG ascites: peritoneal carcinomatosis, pancreatic ascites , tuberculous 
peritonitis, biliary ascites, nephritic syndrome,connective tissue disordes, post 
operative lymphatic leak, intestinal obstruction or infarction. 
Treatment of ascites  
Establishing the cause of ascites is the important aspect of diagnosis. The 
possible reasons  for the ascites in case of cirrhosis of liver are variceal bleed, 
hepatocellular carcinoma with or without portal vein thrombosis, non 
compliance with diuretics ,  use of non steroidal anti inflammatory drugs 
,iatrogenic. 
Sodium restriction is the main stay of treatment of ascites. Sodium intake less 
than 2grms/day is a realistic goal. Salt restricted diet alone will eliminate 
ascites in around 10% of cases. 
Diuretic therapy 
Required in 90% of individuals with ascites, especially those with moderate 
and tense ascites. Complications limiting the use of diuretics are azotemia, 
electrolyte abnormalities, intravascular hypovolemia, hepatic encephalopathy. 
Diuretic approach 
Spiranolactone is the diuretic of choice for single agent therapy of ascites. It is 
less potent natriuretic,hypokalemia uncommon, long half life of spiranalactone 
so once daily dosing is enough. Maximum dosing is 400mg. 
Combination of spiranalactone and furosemide is the most effective treatment 
for ascites with sodium restriction. The initial dosing of spiranalactone is 
100mg and that of furosemide is 40mg. Maximum dosage reached with 
spiranalactone is 400mg/day and that of furosemide is 160mg/day. 
Management of diuretic refractory ascites 
Large volume paracentesis- draining around 5ltrs of ascitic fluid by therapeutic 
paracentesis. Transjugular intra hepatic portosystemic shunt should be 
considered in patients frequently requiring large volume paracentesis. Liver 
transplantation to be considered  for suitable candidates. 
ASCITIC FLUID INFECTIONS 
Ascitic fluid infections can classified  as the following categories 
Spontaneous bacterial peritonitis, culture negative neutrocytic ascites, 
monomicrobial non neutrocytic bacterascites , polymicrobial bacterascites, 
secondary bacterial peritonitis. 
SPONTANEOUS BACTERIAL PERITONITIS has a positive ascitic fluid 
culture and polymorphonuclear cell count more than 250cells/cumm. There  
should be no intraabdominal  surgical source of infection. The most common 
organism are Escherichia coli, streptococcus pneumonia , klebsiella 
pneumonia. Fungi doesnot usually cause spontaneous peritonitis but can occur 
in immunocompromised individuals. Treatment is with third generation 
cephalosporins particularly cefotaxim 2grms intravenous 8th hrly for 5 days. 
Alternate regimens include fluoroquinolones and amoxicillin clavulanic 
acid[28]. 
CULTURE NEGATIVE NEUTROCYTIC ASCITES has a negative ascitic 
fluid culture but polymorhonuclear  cell count more than 250cells/cumm. There 
should be no intra abdominal source of infection. It represents resolution of 
bacterial infection from translocation of gut bacteria secondary to antibacterial 
properties of ascitic fluid[29]. 
Both spontaneous bacterial peritonitis and culture negative neutrocytic ascites 
have similar mortality rates , both entities has to be treated. 
Other causes of neutrocytic ascites should be considered such as peritoneal 
carcinomatosis, pancreatitis , tuberculuos peritonitis, peritonitis related to 
connective tissue diseases, hemorrhage into ascitic fluid. 
MONOBACTERIAL NON NEUTROCYTIC ASCITES is a variant of 
spontaneous bacterial peritonitis in which culture yields a single organism but 
neutrophil count less than 250cells/cumm.  In this situation patient should be 
monitored carefully for development of symptoms of fever , abdominal pain. 
Repeat ascitic fluid cell count should be done and  should be treated if patient 
becomes symptomatic or cell count levels more than 250cells/cumm[30]. 
POLYMICROBIAL ASCITES indicates  polymicrobial growth on culture with 
cell count less than 250cells/cumm. The reason is inadvertent  bowel 
perforation during paracentesis . Decision regarding treatment  is based on cell 
count ,treatment is with broad spectrum antibiotics covering both gram 
positive,  gram negative organisms and anaerobic organisms[31]. 
SECONDARY BACTERIAL PERITONITIS is intrabdominal infection 
occurring in the presence of surgical source of infection like ulcer perforation, 
gall bladder perforation, hepatic abscess rupture. The cell count is more than 
250cells/cumm and culture grows multiple organisms. Other findings indicate 
secondary bacterial infection are glucose less than 50mg/dl, elevated lactate 
dehydrogenase, total protein greater than 1grms/dl. Secondary peritonitis 
should be suspected if repeat paracentesis shows increased cell count even after 
treatment with appropriate antibiotics. 
HEPATIC ENCEPHALOPATHY 
It is a complication arising secondary to liver failure in which the sensorium is 
affected  [32].The important aspect of diagnosis is significant liver disease 
should be present. Hepatic encephalopathy is of three types  
TYPE-A – Related with acute liver failure 
TYPE- B-Opening up of collateral circulation in the absence of liver disease. 
TYPE-C – Related to chronic and end stage liver disease and portal 
hypertension. 
Type C related hepatic encephalopathy has been graded as 4 stages in west 
haven grading of hepatic encephalopathy. 
SONIC( SPECTRUM OF NEUROCOGNITIVE IMPAIRMENT IN 
CIRRHOSIS)  newer classification has been introduced since 2011. According 
to which hepatic encephalopathy is divided into three class  unimpaired , covert 
and overt hepatic encephalopathy[33].  
 Overt hepatic encephalopathy :  varied spectrum of neurologic and 
neuropsychiatric manifestations present. 
 Covert or minimal hepatic encephalopathy : cirrhosis patient with normal 
mental and neurologic status on clinical examination but exhibit reversible and 
quantifiable neurophysiologic and neuropsyciatric abnormalities. 
 
Clinical scales for assessment of OVERT hepatic encephalopathy 
West haven criteria. 
Hepatic encephalopathy scoring algorithm[33]. 
Clinical hepatic encephalopathy staging scale[34]. 
 
PATHOLOGY OF HEPATIC ENCEPHALOPATHY 
There is no single theory which adequately explains the mechanism of hepatic 
encephalopathy. The various theory are  increased ammonia secondary to 
failure in conversion to urea by liver and bypass of portal circulation through 
opened collaterals of portosystemic circulation. The ammonia crosses the blood 
brain barrier and causes changes in astrocytes  that cause swelling of brain  
cells. 
Inflammatory mediators and cytokines play a role along with hyperammonemia 
by altering the permeability of blood brain barrier, microglial activation and 
subsequent production of neurosteroids. 
Increased benzodiazepine like compounds in the brain, manganese 
accumulation in basalganglia and alteration in tryptophan metabolism. 
Recurrent hepatic encephalopathy :  two hepatic encephalopathy episodes in 
one year. 
Covert hepatic encephalopathy :  normal neurological examination with  
neuropsychiatric test abnormality. 
Persistent hepatic encephalopathy : low grade hepatic encephalopathy( covert 
encephalopathy and grade 1 encephalopathy) mental status changes with no 
disorientation. High grade hepatic encephalopathy (stage  2 to stage 4) mental 
status changes with disorientation. Spastic paraparesis is a rare variant of 
hepatic encephalopathy. 
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Laboratory tests in hepatic encephalopathy 
Blood ammonia levels are not frequently measured as it doesnot change the 
treatment . There is not much difference in the value of venous ammonia and 
arterial ammonia levels. Laboratory errors occur while collection of sample and 
the most common errors are  improper collection technique and incorrect 
transportation, hemolysis or use of heparin lock during venous puncture , 
smoking, pollution of laboratory atmosphere. 
ELECTROENCEPHALOGRAM 
The main eeg criterion is slowing of the mean frequency. Sensitivity varies 
from 43% to 100%. 
CRITICAL FLICKER FREQUENCY TEST. 
Based on the relation that reinal gliopathy reflects the cerebral gliopathy in 
hepatic encephalopathy. Correlates  well with traditional pencil and paper 
psychometric test used to dignose hepatic encephalopathy. It helps in 
discriminating stage 0 hepatic encephalopathy from covert and overt 
encephalopathy[35].  
MAGNETIC RESONANCE IMAGING 
The features observed in magnetic resonance imaging are cortical atrophy, 
hyperintensity in t1 weighted images of basal ganglia. Proton MR spectroscopy 
detects a consistent  increase in glutamine to glutamate signal . 
TREATMENT OF HEPATIC ENCEPHALOPATHY 
Generalised care for the unconscious patient . identification of the precipitating 
factors like sepsis,gastrointestinal hemorrhage, constipation,dietery protein 
overload,dehydration,hypokalemia ,alkalosis, poor compliance with lactulose 
therapy. Empiric therapy involves gut cleaning by enemas  and administration 
of lactulose syrup 15 ml initially and increased to 30ml till two to three bowel 
movements are achieved. 
Second line management involves administering gut sterilising agent like 
rifaximine 550mg twice daily, metronidazole 250mg four times daily, 
neomycin 500 mg four times daily. 
Response to treatment  
Patients with overt encephalopathy  ,recovery is possible within 72hrs after 
commencing treatment. Failure to reverse following treatment  ,other secondary 
causes should be considered like wernicke encephalopathy ,subdural 
hemorrhage , dehydration secondary to lactulose administration. 
Type A hepatic encephalopathy 
These account for small number of cases  of hepatic encephalopathy, the 
precipitating factor is unclear, poor response to adequate treatment,cerebral 
edema and intracranial hyprtension  are common in these group of patients and  
often lethal.  
Management of intractable or recurrent hepatic encephalopathy 
Liver transplantation  and  Modification of  existing portosystemic shunt are 
the options available for intractable or recurrent hepatic encephalopathy. 
Hepatorenal syndrome 
It is elevation of serum creatinine more than 1.5 mg/dl ,occurring in a patient 
with advanced liver disease and portal hypertension. It occurs due  to decreased 
glomerular filtrarion rate  and renal plasma flow, secondary to changes 
occurring in systemic hemodynamics and activation of endogeneous vasoactive 
system[36]. 
Pathogenesis  
There is a arterial vasodilatation that occurs  by mechanisms not known  
secondary to portal hypertension. Vasodilatation occurs mainly in splanchnic 
circulation ,there by vasoconstrictor systems are activated  which causes 
compensation for systemic vasodilatation. 
Diagnostic criteria for hepatorenal syndrome  
Cirrhosis with ascites  
Serum creatinine level greater than 1.5mg/dl. 
Lack of improvement in serum creatinine level after 2 days following diuretic 
withdrawal and volume expansion with albumin. 
Lack of underlying kidney disease as shown by proteinuria less than 500 
mg/day  or recent use of nephrotoxic agents. 
Absence of shock 
Hepatorenal syndrome is classified into two types type-1 hrs seen in patients 
with cirrhosis going for sudden decompensation and type -2 hrs seen in patients 
with long standing refractory ascites. 
Type-1 hepatorenal syndrome 
Rapidly rising serum creatinine with level reaching more than 2.5mg/dl within 
2 weeks. Occurs following bacterial infection ,gastrointestinal hemorrhage  or 
therapeutic paracentesis without plasma expansion. Median survival time is 2 
weeks. 
Type-2 hepatorenal syndrome 
Moderate and stable renal failure occurs . It occurs with relatively preserved 
liver , median survival is approximately six weeks.  
It is important to rule out other causes of acute kidney injury in cirrhosis like 
acute tubular nescrosis, glomerular disease, druginduced kidney injury , 
prerenal azotemia. 
Treatment of hepatorenal syndrome  
Liver transplantation is the treatment of choice in patients with hepatorenal 
syndrome. 
Medical management is by administration of  a vasoconstrictor and a volume 
expander 
Terlipressin 2mg every 4-6hrly along with albumin administration has reversed 
the  renal injury in 60% of patients[37]. Recurrence of   hepatorenal syndrome 
is around 50% and retreatment is effective. 
Cirrhosis patients are assessed in severity by application of child pugh scoring  
which consists of the following  variables  albumin, ascites, bilirubin, 
prothrombin time, international standardized ratio, encephalopathy and each 
variable is assigned a score based on its severity of derangement. There was no 
serum biomarker which reflects on the severity of cirrhosis. Recently serum 
prolactin has been studied as a possible biomarker for the estimation of 
cirrhosis severity. The possible explanations given for the elevation are 
,deranged aminoacid metabolism which leads to decreased dopaminergic levels 
in central nervous system which also has a role as prolactin inhibiting factor. 
There by as the severity of cirrhosis  increases and the aminoacid metabolism 
also deranged causing secondary elevation of serum prolactin. In  few  studies 
serum prolactin levels has  been demonsrared as a  individual  mortality 
indicator  irrespective of  cirrhosis severity by child pugh scoring[38,39,40].  
PROLACTIN 
It is also called as lactogenic or mammotrophic or galactopoetic hormone.  
Prolactin is synthesized in the acidophil cells . physiologically the cell increase 
in number and constitute over 50%  of pituitary acidophils. It contains 198 
aminoacids, molecular weight 25000 , halflife of 20minutes. It receptors has 
similarity to growth hormone receptors  .  Normal serum prolctin levels in 
males -2 to 18ng/ml, female – 2 to 29ng/ml.   
CONTROL OF SECRETION 
Stimulus for prolactin secretion act via stimulating  prolactin releasing  factor , 
prolactin secretion increases 2-3hrs after sleeponset, various stress leads to 
increase in prolactin secretion, pregnancy , breast stimulation , primary 
hypothyroidism , dopamine antagonist, adrenergic blockers and section of 
pituitary stalk. 
STIMULI THAT INHIBIT PROLACTIN SECRETION 
Primarily the control of prolactin secretion is mediated through prolactin  
inhibiting factor, secreted  tonically by hypothalamus into the pituitary by 
hypothalamo-pituitary portal vessels. Dopamine is the main prolactin inhibiting 
factor. Drugs like serotonin antagonists and dopamine agonists will inhibit 
prolactin secretion. 
ACTIONS OF PROLACTIN 
Plays an important role in the development of  the mammary gland and in milk 
synthesis. Leads to differentiation of lobules into alveoli .  Immediately  after 
delivery prolactin stimulates galactosyltransferase activity leading to synthesis 
of lactose. High prolactin levels inhibit lutenising hormone and leads to 
anovulation.  
 
HYPERPROLACTINEMIA 
Since prolactin levels varies with various stimulus appropriate estimation is 
done by measuring early morning fasting levels, normally it should be less than  
20ng/ml. 
Whenever hyperprolactinemia is present it is important to rule out secondary 
causes such as drug induced, hypothyroidism , chronic kidney disease. After 
exclusion of secondary causes primary pituitary mass lesion should be ruled out 
by imaging, around 10% of cases of hyperprolactinemia will have 
micropituitary adenoma  which is not pickedup by brain imaging. 
RELATION BETWEEN PROLACTIN AND CIRRHOSIS 
Cirrhosis is a  end stage pathology of liver following chronic inflammation , 
which is diagnosed based on clinical , biochemical , imaging features . Its 
severity is being assessed by child pugh scoring which has variables indicating 
the liver function status. There  is no serological biochemical marker  till now 
which has been predicting the severity of liver damage and comparable to child 
pugh scoring.  
Recent studies has found that serum prolactin levels has been increased in 
patients with cirrhosis ,without any other cause for elevation present in these 
patients. The rise is also comparable to the severity as assessed by child pugh 
scoring. In few studies  very high serum prolactin has been determined to be as 
a mortality indicator when levels cross 50ng/ml. Few studies has not shown 
consistent result and elevated prolactin  in cirrhosis should evaluated 
separately.     
 CONCEPT PAPER FOR- A STUDY TO CORRELATE SERUM 
PROLACTIN AND CHILD PUGH SCORING IN CIRRHOSIS 
BACKGROUND INFORMATION : 
Cirrhosis is a chronic condition affecting the liver characterized by replacement 
of hepatocytes by fibrous tissue , due to loss of hepatocytes , various 
derangements occur in the body manifesting as ascites ,esophageal and gastric 
varices, portal hypertension , hyperspleenism, spontaneous bacterial peritonitis, 
hepatorenal syndrome, hepatic encephalopathy, hepatocellular carcinoma, 
hepatopulmonary syndrome. 
The various causes of cirrhosis are alcoholconsumption, viral infections , 
metabolic causes( Wilsons disease, alpha 1 antitrysin deficiency, 
hemochromatosis), primary biliary cirrhosis, primary sclerosing cholangitis.  
The severity of cirrhosis  is usually assessed by child pugh scoring which 
consists of the following variables albumin , ascites, bilirubin, prothrombin 
time ,  international standardized ratio and hepatic encephalopathy.  
Recently studies has been conducted to determine a appropriate serum marker 
for assessing the severity of cirrhosis . prolactin has been determined to 
increase in cirrhosis and its level has been found to correlate to severity 
assessed by child pugh scoring .  
Normal serum prolactin levels  
Males  : 2 to 18ng/ml 
Females : 2 to 29ng/ml. 
OBJECTIVE: 
To determine the correlation between serum prolactin levels and child pugh 
scoring in cirrhosis patients 
PLACE OF STUDY: 
Department of medicine ,Stanley medical college and hospital. 
STUDY POPULATION: 
100 patients of cirrhosis of varied etiology. 
Age more than 18 years. 
STUDY DESIGN  
Longitudinal study 
OPERATIONAL DEFINTION 
Diagnosis of cirrhosis is based on clinical , biochemical evidence and the 
presence of esophageal varices , ascites with albumin gradient more than 
1.1grms/l. 
 
INCLUSION CRITERIA: 
All cirrhosis patients of varied etiology. 
Age more than 18 years. 
EXCLUSION CRITERIA: 
Acute liver cell failure  
Headinjury  
Hypothyroidism 
Drugs increasing serum prolactin levels 
Chronic kidney disease 
Cranial surgery. 
METHODOLOGY: 
A total of 100 cirrhosis patients admitted in medical wards in Stanley hospital 
Chennai  are included in the present study. Informed consent will be obtained 
from each patients. Patients are subjected for clinical examination and followed 
by relevant investigation. Patients improvements will be observed once in 3 
days till discharge. 
Patients will undergo the following investigations 
Complete blood count 
Random blood sugar  
Renal function test 
Liver function test 
Serum ascitic fluid analysis 
Prothrombin time and INR 
Viral markers 
Ultrasound abdomen 
Oesophagogastroduodenoscopy 
Serum prolactin 
Child pugh scoring and West haven criteria are applied to the subjects to 
determine severity of cirrhosis and grading of hepatic encephalopathy.  
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BENEFITS OF STUDY 
 If association determined, serum prolactin can be used as a marker for 
determining severity of cirrhosis. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Groups  
Groups  Definition  Number 
Elevated Prolactin Group  Male - > 18ng/ml 
 Female- > 
29ng/ml 
91 
Normal Prolactin Group  Male -2 to 
18ng/ml 
 Female-2 to 
29ng/ml 
9 
 
Null Hypothesis 
 
 
Null Hypothesis : H0  
 
Elevated prolactin group equal in effect compared to 
normal prolactin group 
 
Alternate Hypothesis : H1  
 
Elevated prolactin group hazardous in effect 
compared to normal prolactin group  
 
 
Data Analysis 
 Descriptive statistics was done for all data and were reported in terms of mean values 
and percentages. Suitable statistical tests of comparison were done. Continuous 
variables were analysed with the unpaired t test.. Categorical variables were analysed 
with the Chi-Square Test and Fisher Exact Test. Statistical significance was taken as P 
< 0.05. The data was analysed using SPSS version 16 and Microsoft Excel 2007. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                                                                                                     
Age  
 
 
Age Elevated 
Prolactin 
Group 
Normal 
Prolactin 
Group 
Combined Elevated 
Prolactin 
Group 
(%) 
Normal 
Prolactin 
Group 
(%) 
Combined 
(%) 
≤ 40 
years 
8 0 8 8.79 0.00 8.00 
41-50 
years 
40 3 43 43.96 33.33 43.00 
51-60 
years 
29 5 34 31.87 55.56 34.00 
61-70 
years 
13 1 14 14.29 11.11 14.00 
71-80 
years 
1 0 1 1.10 0.00 1.00 
Total 91 9 100 100 100 100 
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Age 
≤ 40 years 41-50 years 51-60 years 61-70 years 71-80 years 
 Among the study patients, there was no statistically significant difference in 
relation to age distribution between elevated prolactin group (mean=50.74, 
SD=8.94) and normal prolactin group (mean=53.11, SD=6.72) with a p value 
of <0.05 as per unpaired t test. Therefore we fail to reject the null hypothesis 
that there is no difference in age distribution between the study groups. 
  
Age Distribution Elevated 
Prolactin Group 
Normal Prolactin 
Group 
Combined 
Mean 50.74 53.11 50.95 
SD 8.94 6.72 8.76 
P value 
Unpaired t Test 
0.4407 
Gender  
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Elevated Prolactin Group Normal Prolactin Group Combined 
Gender 
Male Female 
Gender Elevated 
Prolactin 
Group 
Normal 
Prolactin 
Group 
Combined Elevated 
Prolactin 
Group 
(%) 
Normal 
Prolactin 
Group 
(%) 
Combined 
(%) 
Male 83 0 83 91.21 0.00 83.00 
Female 8 9 17 8.79 100.00 17.00 
Total 91 9 100 100 100 100 
P value 
Fishers Exact Test 
<0.0001 
 Among the study patients, there was a statistically significant difference in 
relation to gender status between elevated prolactin group (majority are males– 
91.21%) and normal prolactin group (majority are females – 100.00% ) with a 
p value of <0.05 as per fishers exact test. Therefore we reject the null 
hypothesis that there is no difference in gender status between the study groups 
Discussion  
The incidence of female gender was significantly less in elevated prolactin 
group compared to normal prolactin group by a percentage difference of 91.21 
percentage points  (91% lower). This difference is significant with a p-value of 
<0.0001 as per fishers exact test.  
 
 
 
 
 
 
 
 
 
 Serum Albumin 
 
 
 
Serum 
Albumin 
Elevated 
Prolactin 
Group 
Normal 
Prolactin 
Group 
Combined Elevated 
Prolactin 
Group 
(%) 
Normal 
Prolactin 
Group 
(%) 
Combined 
(%) 
≤ 1.5 g/dl 0 0 0 0.00 0.00 0.00 
1.6-2.5 
g/dl 
12 2 14 13.19 22.22 14.00 
2.6-3.5 
g/dl 
66 3 69 72.53 33.33 69.00 
3.6-5.5 
g/dl 
13 4 17 14.29 44.44 17.00 
Total 91 9 100 100 100 100 
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Elevated Prolactin Group Normal Prolactin Group Combined 
Serum Albumin 
≤ 1.5 g/dl 1.6-2.5 g/dl 2.6-3.5 g/dl 3.6-5.5 g/dl 
 Serum Albumin 
Distribution 
Elevated 
Prolactin Group 
Normal Prolactin 
Group 
Combined 
Mean 3.00 3.16 3.02 
SD 0.50 0.61 0.51 
P value  
Unpaired t Test 
0.3843 
 
 
Among the study patients, there was no statistically significant difference in 
relation to serum albumin distribution between elevated prolactin group 
(mean=3.00, SD=0.50) and normal prolactin group (mean=3.16, SD=0.61) with 
a p value of <0.05 as per unpaired t test. Therefore we fail to reject the null 
hypothesis that there is no difference in serum albumin distribution between the 
study groups 
 
 
 
 
 
  
Total Bilirubin 
 
  
 
Total Bilirubin Elevated 
Prolactin 
Group 
Normal 
Prolactin 
Group 
Combined Elevated 
Prolactin 
Group 
(%) 
Normal 
Prolactin 
Group 
(%) 
Combined 
(%) 
≤ 0.3 mg/dL 62 8 70 68.13 88.89 70.00 
0.4 -1.0 mg/dL 26 0 26 28.57 0.00 26.00 
1.1-1.9 mg/dl 3 1 4 3.30 11.11 4.00 
Total 91 9 100 100 100 100 
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Elevated Prolactin Group Normal Prolactin Group Combined 
Total Bilirubin 
≤ 0.3 mg/dL 0.4 -1.0 mg/dL 1.1-1.9 mg/dl 
  
Total Bilirubin 
Distribution 
Elevated Prolactin 
Group 
Normal Prolactin 
Group 
Combined 
Mean 1.48 1.51 1.49 
SD 0.43 0.50 0.43 
P value  
Unpaired t Test 
0.8557 
  
Among the study patients, there was no statistically significant difference in 
relation to total bilirubin distribution between elevated prolactin group 
(mean=1.48, SD=0.43) and normal prolactin group (mean=1.51, SD=0.50) with 
a p value of <0.05 as per unpaired t test. Therefore we fail to reject the null 
hypothesis that there is no difference in total bilirubin distribution between the 
study groups. 
  
Prothrombin Time 
 
  
 
Prothrombin 
Time 
Elevated 
Prolactin 
Group 
Normal 
Prolactin 
Group 
Combined Elevated 
Prolactin 
Group 
(%) 
Normal 
Prolactin 
Group 
(%) 
Combined 
(%) 
≤ 13.5 secs 1 0 1 1.10 0.00 1.00 
13.6-15.0 secs 1 0 1 1.10 0.00 1.00 
15.1-20.0 secs 60 6 66 65.93 66.67 66.00 
20.1-25.0 secs 25 3 28 27.47 33.33 28.00 
25.1-30.0 secs 4 0 4 4.40 0.00 4.00 
Total 91 9 100 100 100 100 
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Prothrombin Time 
≤ 13.5 secs 13.6-15.0 secs 15.1-20.0 secs 20.1-25.0 secs 25.1-30.0 secs 
  
Prothrombin Time 
Distribution 
Elevated 
Prolactin Group 
Normal Prolactin 
Group 
Combined 
Mean 19.64 18.78 19.56 
SD 2.71 2.73 2.71 
P value  
Unpaired t Test 
0.3665 
  
Among the study patients, there was no statistically significant difference in 
relation to prothrombin time distribution between elevated prolactin group 
(mean=19.64, SD=2.71) and normal prolactin group (mean=18.78, SD=2.73) 
with a p value of <0.05 as per unpaired t test. Therefore we fail to reject the 
null hypothesis that there is no difference in prothrombin time distribution 
between the study groups. 
 
  
International Normalized Ratio 
 
  
 
International 
Normalized 
Ratio 
Elevated 
Prolactin 
Group 
Normal 
Prolactin 
Group 
Combined Elevated 
Prolactin 
Group 
(%) 
Normal 
Prolactin 
Group 
(%) 
Combined 
(%) 
≤ 1 2 0 2 2.20 0.00 2.00 
1.1-1.2 25 5 30 27.47 55.56 30.00 
1.3-1.4 35 1 36 38.46 11.11 36.00 
1.5-1.6 19 3 22 20.88 33.33 22.00 
1.7-1.8 10 0 10 10.99 0.00 10.00 
Total 91 9 100 100 100 100 
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 International Normalized Ratio 
≤ 1 1.1-1.2 1.3-1.4 1.5-1.6 1.7-1.8 
  
International 
Normalized Ratio 
Distribution 
Elevated 
Prolactin Group 
Normal Prolactin 
Group 
Combined 
Mean 1.36 1.31 1.35 
SD 0.20 0.19 0.20 
P value  
Unpaired t Test 
0.4956 
  
Among the study patients, there was no statistically significant difference in 
relation to international normalized ratio distribution between elevated 
prolactin group (mean=1.36, SD=0.20) and normal prolactin group 
(mean=1.31, SD=0.19) with a p value of <0.05 as per unpaired t test. Therefore 
we fail to reject the null hypothesis that there is no difference in International 
Normalized Ratio distribution between the study groups. 
  
Ascites 
 
  
 
Ascites Elevated 
Prolactin 
Group 
Normal 
Prolactin 
Group 
Combined Elevated 
Prolactin 
Group 
(%) 
Normal 
Prolactin 
Group 
(%) 
Combined 
(%) 
Nil 15 2 17 16.48 22.22 17.00 
Mild 43 3 46 47.25 33.33 46.00 
Moderate 28 3 31 30.77 33.33 31.00 
Severe 5 1 6 5.49 11.11 6.00 
Total 91 9 100 100 100 100 
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P value 
Fishers Exact Test 
0.6219 
  
Among the study patients, there was no statistically significant difference in 
relation to ascites status between elevated prolactin group (majority had mild 
ascites– 47.25%) and normal prolactin group (majority had mild/moderate 
ascites– 33.33%) with a p value of <0.05 as per fishers exact test. Therefore we 
fail to reject the null hypothesis that there is no difference in gender status 
between the study groups. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
Encephalopathy Grade 
  
 
Encephalopathy 
Grade 
Elevated 
Prolactin 
Group 
Normal 
Prolactin 
Group 
Combined Elevated 
Prolactin 
Group 
(%) 
Normal 
Prolactin 
Group 
(%) 
Combined 
(%) 
Grade 1 44 5 49 48.35 55.56 49.00 
Grade 2 27 2 29 29.67 22.22 29.00 
Grade 3 1 1 2 1.10 11.11 2.00 
Grade 4 3 0 3 3.30 0.00 3.00 
Nil 16 1 17 17.58 11.11 17.00 
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Elevated Prolactin Group Normal Prolactin Group Combined 
Encephalopathy Grade 
Grade 1 Grade 2 Grade 3 Grade 4 Nil 
Total 91 9 100 100 100 100 
P value 
Fishers Exact Test 
0.2791 
  
Among the study patients, there was no statistically significant difference in 
relation to encephalopathy grade status between elevated prolactin group 
(majority had grade 1 encephalopathy – 48.35%) and normal prolactin group 
(majority had grade 1 encephalopathy – 55.56%) with a p value of <0.05 as per 
fishers exact test. Therefore we fail to reject the null hypothesis that there is no 
difference in encephalopathy grade status between the study groups. 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 Varices 
 
  
 
Varices Elevated 
Prolactin 
Group 
Normal 
Prolactin 
Group 
Combined Elevated 
Prolactin 
Group 
(%) 
Normal 
Prolactin 
Group 
(%) 
Combined 
(%) 
Present 33 4 37 36.26 44.44 37.00 
Absent 58 5 63 63.74 55.56 63.00 
Total 91 9 100 100 100 100 
P value 
Fishers Exact Test 
0.6277 
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Among the study patients, there was no statistically significant difference in 
relation to varices status between elevated prolactin group (majority had absent 
varices– 63.74%) and normal prolactin group (majority had absent varices – 
55.56%) with a p value of <0.05 as per fishers exact test. Therefore we fail to 
reject the null hypothesis that there is no difference in varices status between 
the study groups. 
Etiology 
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Alcohol Cryptogenic Viral 
 Etiology 
Elevated 
Prolactin 
Group 
Normal 
Prolactin 
Group 
Combined Elevated 
Prolactin 
Group 
(%) 
Normal 
Prolactin 
Group 
(%) 
Combined 
(%) 
Alcohol 64 7 71 70.33 77.78 71.00 
Cryptogenic 8 1 9 8.79 11.11 9.00 
Viral 19 1 20 20.88 11.11 20.00 
Total 91 9 100 100 100 100 
P value 
Fishers Exact Test 
0.6385 
  
Among the study patients, there was no statistically significant difference in 
relation to etiology status between elevated prolactin group (majority had 
alcohol etiology– 70.33%) and normal prolactin group (majority had alcohol 
etiology – 77.78%) with a p value of <0.05 as per fishers exact test. Therefore 
we fail to reject the null hypothesis that there is no difference in etiology status 
between the study groups. 
 
 
 
Spontaneous Bacterial Peritonitis 
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Spontaneous Bacterial Peritonitis 
Present Absent 
Spontaneous 
Bacterial 
Peritonitis 
Elevated 
Prolactin 
Group 
Normal 
Prolactin 
Group 
Combined Elevated 
Prolactin 
Group 
(%) 
Normal 
Prolactin 
Group 
(%) 
Combined 
(%) 
Present 25 4 29 27.47 44.44 29.00 
Absent 66 5 71 72.53 55.56 71.00 
Total 91 9 100 100 100 100 
P value 
Fishers Exact Test 
0.2844 
 Among the study patients, there was no statistically significant difference in 
relation to spontaneous bacterial peritonitis status between elevated prolactin 
group (majority had no SBP – 72.53%) and normal prolactin group (majority 
had no SBP – 55.56%) with a p value of <0.05 as per fishers exact test. 
Therefore we fail to reject the null hypothesis that there is no difference in 
spontaneous bacterial peritonitis status between the study groups.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Outcome 
 
  
 
Outcome Elevated 
Prolactin 
Group 
Normal 
Prolactin 
Group 
Combined Elevated 
Prolactin 
Group 
(%) 
Normal 
Prolactin 
Group 
(%) 
Combined 
(%) 
Improved 52 7 59 57.14 77.78 59.00 
Not Improved 39 2 41 42.86 22.22 41.00 
Total 91 9 100 100 100 100 
P value 
Fishers Exact Test 
0.0366 
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 Among the study patients, there was a statistically significant difference in 
relation to outcome status between elevated prolactin group (majority 
improved– 57.14%) and normal prolactin group (majority improved – 77.78% ) 
with a p value of <0.05 as per fishers exact test. Therefore we reject the null 
hypothesis that there is no difference in outcome status between the study 
groups 
Discussion  
The incidence of not improved outcome was significantly more in elevated 
prolactin group compared to normal prolactin group by a percentage difference 
of 20.63 percentage points (48% higher). This difference is significant with a p-
value of 0.0366 as per fishers exact test.  
 
 
 
 
 
 
 
 
Child Pugh Score 
 
  
Child 
Pugh 
Score 
Elevated 
Prolactin 
Group 
Normal 
Prolactin 
Group 
Combined Elevated 
Prolactin 
Group 
(%) 
Normal 
Prolactin 
Group 
(%) 
Combined 
(%) 
Class A 11 5 16 12.09 55.56 16.00 
Class B 32 2 34 35.16 22.22 34.00 
Class C 48 2 50 52.75 22.22 50.00 
Total 91 9 100 100 100 100 
P value 
Fishers Exact Test 
0.0078 
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 Among the study patients, there was a statistically significant difference in 
relation to child pugh score status between elevated prolactin group (majority 
were class B – 35.16%) and normal prolactin group (majority were Class A – 
55.56% ) with a p value of <0.05 as per fishers exact test. Therefore we reject 
the null hypothesis that there is no difference in child pugh score status 
between the study groups 
 
Discussion  
The incidence of class A child pugh score which signifies 100% 1 year survival 
and 85% 2 year survival was significantly less in elevated prolactin group 
compared to normal prolactin group by a percentage difference of 43.47 
percentage points  (78% lower).  
The incidence of class C child pugh score which signifies 45% 1 year survival 
and 35% 2 year survival was significantly more in elevated prolactin group 
compared to normal prolactin group by a percentage difference of 30.53 
percentage points  (58% higher).  
This difference is significant with a p-value of 0.0078 as per fishers exact test.  
 
 
 
 CONCLUSION  
The conclusions obtained from the study  
Male cirrhotic patients have elevated serum prolactin level 11.38 times more 
than female cirrhotic patients 
Cirrhotic patients with elevated prolactin level are associated with poor 
prognosis 
Patients belonging to class A child pugh scoring have low levels of prolactin 
compared to class C child pugh. 
 
LIMITATIONS OF THE STUDY 
Small   sample size 
Other variables which determine the outcome to be considered.  
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I will not object if the results of this study are getting published in any medical 
journal, provided my personal identity is not revealed. 
I know what I am supposed to do by taking part in this study and I assure that I 
would extend my full cooperation for this study.   
  
 Volunteer:      Witness: 
Name and address       Name and address  
Signature/thumb impression:   Signature/thumb impression 
Date:       Date: 
 Investigator Signature and date 
                         
  GOVT. STANLEY MEDICAL COLLEGE, CHENNAI – 600001 
INFORMED CONSENT 
A STUDY TO CORRELATE SERUM PROLACTIN AND CHILD 
PUGH SCORING IN CIRRHOSIS 
     AT GOVERNMENT STANLEY HOSPITAL, CHENNAI. 
 
நான் இந்த ஆராய்ச்சியில் விவரங்களை முற்றிலும் புாிந்து ககாண்டேன். 
ஆய்வில் பங்கு எடுத்து டபாது, சாத்தியமான அபாயங்கள் மற்றும் பயன்களை பற்றி 
நான் அறிந்துள்டைன். 
நான் எந்தகவாரு டவளையிலும் ஆய்வில் இருந்து திரும்ப முடியும், அதன் பின்னர், 
நான் வழக்கம் டபால் மருத்துவ சிகிச்ளச கபற முடியும் என்று புாிந்துககாள்கிடறன் 
நான் ஆய்வில் பங்கு எடுத்து பணம் எளதயும் கபற முடியாது என்று அறிந்துள்டைன். 
இந்த ஆய்வின் முடிவுகள் எந்த கமடிக்கல் ஜர்னலில் கவைியிேப்பே இருந்தால் நான் 
எதிர்க்கவில்ளை, என் தனிப்பட்ே அளேயாைத்ளத கவைிப்படுத்தப்பட்டு இருக்க 
கூோது. 
நான் இந்த ஆய்வில் பங்ககடுப்பதன் மூைம் நான் என்ன கசய்ய டபாகிடறன் என்று 
கதாியும் 
நான் இந்த ஆய்வில் என் முழு ஒத்துளழப்ளபயும் ககாடுப்டபன் என்று 
உறுதியைிக்கிடறன். 
 
தன்னார்வைர்           சாட்சி  
கபயர் மற்றும் முகவாி       கபயர் மற்றும் முகவாி 
ளககயாப்பம் / விரல் டரளக:      ளககயாப்பம் / விரல் 
டரளக: 
 
 
ஆராய்ச்சியாைராக      ளககயாப்பம் மற்றும் டததி     
 
            
 
  
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 ABBREIVATIONS 
1. CBC - COMPLETE BLOOD COUNT 
2. TC – TOTAL COUNT 
3. RFT - RENAL FUNCTION TEST 
4. LFT – LIVER FUNCTION TEST 
5. T.B – TOTAL BILIRUBIN 
6. D.B – DIRECT BILURUBIN 
7. SAP – SERUM ALKALINE PHOSPATASE 
8. AST – ASPARTATE TRANSAMINASE 
9. ALT – ALANINE TANSAMINASE 
10. PT – PROTHROMBIN TIME 
11. INR – INTERNATIONAL NORMALISED RATIO 
12. OGD SCOPY – OESOPHAGO GASTRODUODENOSCOPY 
13. HBsAg – SURFACE ANTIGEN OF HEPATITIS B 
14. ANTI HCV – ANTIBODY FOR HEPATITIS C  
15. USG – ULTRASOUND  
16. SAAG – SERUM ASCITIC ALBUMIN GRADIENT 
17. CT - COMPUTED TOMOGRAPHY 
18. MRI  - MAGNETIC RESONANCE IMAGING  
